Ironwood Investment Management LLC Has $954,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Ironwood Investment Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 3.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 6,787 shares of the company’s stock after acquiring an additional 220 shares during the period. Ironwood Investment Management LLC’s holdings in Johnson & Johnson were worth $954,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the stock. Cigna Investments Inc. New lifted its stake in Johnson & Johnson by 23.1% in the 2nd quarter. Cigna Investments Inc. New now owns 100,271 shares of the company’s stock valued at $14,102,000 after purchasing an additional 18,848 shares during the last quarter. Parametrica Management Ltd lifted its position in Johnson & Johnson by 5.1% during the second quarter. Parametrica Management Ltd now owns 10,926 shares of the company’s stock worth $1,534,000 after acquiring an additional 528 shares during the last quarter. Private Advisor Group LLC lifted its position in Johnson & Johnson by 6.2% during the second quarter. Private Advisor Group LLC now owns 302,163 shares of the company’s stock worth $42,494,000 after acquiring an additional 17,509 shares during the last quarter. Argent Wealth Management LLC lifted its position in Johnson & Johnson by 0.8% during the second quarter. Argent Wealth Management LLC now owns 24,799 shares of the company’s stock worth $3,670,000 after acquiring an additional 188 shares during the last quarter. Finally, Wealthfront Advisers LLC lifted its position in Johnson & Johnson by 25.6% during the second quarter. Wealthfront Advisers LLC now owns 93,452 shares of the company’s stock worth $13,142,000 after acquiring an additional 19,046 shares during the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

Several equities research analysts have issued reports on JNJ shares. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a research report on Tuesday, July 7th. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $161.00 to $164.00 in a research report on Monday, July 20th. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Friday, September 4th. Citigroup lifted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Finally, Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and a consensus target price of $163.00.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.

NYSE:JNJ traded up $1.49 during mid-day trading on Friday, reaching $148.40. The stock had a trading volume of 194,859 shares, compared to its average volume of 5,840,619. The stock has a 50-day simple moving average of $149.40 and a two-hundred day simple moving average of $144.20. The stock has a market capitalization of $394.13 billion, a PE ratio of 21.63, a P/E/G ratio of 3.32 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. The business had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period last year, the firm posted $2.58 earnings per share. Equities analysts expect that Johnson & Johnson will post 7.85 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a $1.01 dividend. The ex-dividend date of this dividend was Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a yield of 2.72%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.